BEGI - Link to the trades:.....
***Link to 88%-https://www.barchart.com/stocks/quotes/BEGI/opinion
🍎FRITTELLE DI MELE - 🍎(APPLES FRITTERS)🍎
*** Quick- Easy- Delicious***
*150 g. Plain Flower
* 200 ml. Milk
* Pinch of Baking Powder
*4 Large Apples
*Oil for Shallow Frying
*1/2 Cup of Sugar - To Sprinkles over the Apples Fritters
*In a Bowl whisk together the eggs, milk, flower and a pinch of baking powder until the mixture is smooth. Set aside.
*Peel the apples an remove the core, then cut the apples into slice 1cm thick
*Preheat 1/2 cm oil in a large frypan over medium heat (The oil is ready for frying when a drop of the batter sizzles). Dip an apple slice into the batter coating evenly, then gently place into the frypan
*Repeat with as many slice that fit comfortably in your frypan
*Fry till golden on both sides then remove and sprinkle on some sugar
*Repeat with the remaining batter and apples slice then serve warm or cold
*N.B. Use little oil as need it...
ABQQ- - Link to the trades.....
***Link to 88%-https://www.barchart.com/stocks/quotes/ABQQ/opinion
***Insider Trading .....
UNITY MAKES STRENGHT
ZHUD - From The Board.... By MrNormall- Thursday, October 26, 2023 5:52:04 PM- Post# 19922
$ZHUD In a matter of 2 days
Verified The Profile, uploaded all Fins necessary for Pink Current and Announced Several Interested Parties for Merger into the Shell
Amazing work here and Super Clean shell with Great Share Structure.
Thanks, Janet! Got filled this morning!
RAKR -- Collaboration with European Union......
Miranda Produces Solutions For A Better Environment
Unique Wastewater Treatment Systems
Miranda is an engineering, consultancy, manufacturing and R&D company focused in the treatment of water, wastewater and reuse of treated water.
We produce technology for environment friendly, sustainable, cost effective, efficient, odor-less, compact and modular wastewater treatment systems. We exceed all required discharge standards worldwide.
Further more Miracell® is the only wastewater treatment system that is specifically designed with an aesthetically pleasing appearance as much as functionality.
Wishing you the Very Best
Enjoy the Weekend
Thanks, Janet, I learning from you!
SFLM- Looks interesting.....Bought some Shares....
SFLM - Link to the trades.....
***Link to 96%-https://www.barchart.com/stocks/quotes/SFLM/opinion
***Link to the trades.....
BDPT - Link to the trades.....
***Link to 88%-https://www.barchart.com/stocks/quotes/BDPT/opinion
BDPT Up 800% In One And A Half Weeks Amid Multiple ...
Penny Stock Dream
http://www.pennystockdream.com › blog › bdpt-up-8...
Jun 19, 2023 — BioAdaptives, Inc., (OTC PINK: BDPT) gained 800% in the past one and a half ... pennystockdream.com regularly shares research with other .
BDPT - Link to the trades.....
***UNITY MAKE STRENTGH!.....
Why is the world full of shitty people?
This People are mean, selfish , arrogant. Such people always try to prove they are good and they do so by showing others are not good enough. Such people never regret if they do something wrong. They are so obsessed with themselves and are far from humanity. It's good sometimes to have shitty people around to know the worth of good people.
***The best but the hardest way to deal with this kind of people is to avoid them completely.
AMC- Interesting Post From :Gollums Stocks- Saturday, August 12, 2023 4:53:43 PM -Post# 126237
NEW $AMC $APE INVESTORS & LONGS Must Read!!!
***At the very least read the highlights but really, it's only about a 3-5 min read tops and well worth the investment of time
GRST - ARIA -> https://www.ariafl.com/
"Mr. Shawn Leon, Company CEO, reported, "The closing of this deal is the result of a lot of hard work and effort and has directly benefited our shareholders. It is a huge improvement in the overall health of the Company. We have managed to keep our issued common stock static since March 2, 2022, which was difficult given the large amount of convertible debt we carried throughout that time. This real estate deal has eliminated a lot of debt, including all variable rate convertible debt and the Company is now free to focus on growth."
*** VERY GOOD PR***
Seeking Alpha | Stock Market Analysis & Tools for Investors
Join Seeking Alpha, the largest investing community in the world. Get stock market news and analysis, investing ideas, earnings calls, charts and portfolio ...
AMC -Goldman Sachs raises AMC Entertainment's price target to ...
https://news.investorturf.com › goldman-sachs-raises-a...
11 hours ago — The Goldman Sachs Group, a renowned financial institution, recently raised AMC Entertainment's price target from $160.00 to $175.00.
DBMM- By: noradio- Post# 315784 Tuesday, July 25, 2023 5:10:07 PM
It's gone up from .25 percent beginning of this year to 8.04 percent today.
INTERESTING.... << There are now attorneys specializing in defamation that damage businesses>> -
***If the majority shareholder has improperly taken assets out of the corporation or acted on behalf of the corporation without authority in bad faith, the courts can authorize any shareholder to start and oversee a lawsuit in the corporation's name against the shareholder who acted in bad faith.
INTERESTING - But That’s Just My Opinion. Or Is It Defamation?
***Posted in Commercial Litigation, Defamation
Everyone is entitled to their own opinions.
Most of us were taught this maxim at an early age. But while the fundamental principle behind this saying holds true today, the reality is a little more complicated, especially with current technology. Now, with a single cellphone, practically anyone can publish their opinions online for the entire world to see. This has led to the discovery by many persons (especially in recent times) that tweeting or posting their “unpleasant” opinions online can result in losing their jobs. Everyone is still entitled to their own opinions, but not necessarily to publishing it, at least not without consequences. In fact, you might not even be legally entitled to publishing your opinion if it is considered defamation.
<< there are now attorneys specializing in defamation that damage businesses - earning multiple 6-figure sums for their clients>>
WealthCampus - By Profe$$or - Saturday, September 10, 2016 12:00:47 PM - Post# 2
The main focus here is to compound our gains. Too many people enter the stock market with the intent of trying to hit a home run. Swinging for the fences also gives you a high strike out ratio. It is important to compound your gains and go for the singles and doubles and you will find that you eventually hit triples and home runs as well. The chart below shows how you can turn only 3k into 1 million dollars in 200 steps. So join me in moving up the steps of our compounding gains chart. Compound those gains!
CRSP - ***Guide to the First Ever FDA CRISPR Approval Expected this Year by CRISPR & Vertex (XDNA ETF Companies)
APR 21, 2023 2:25PM EDT
While being a newer technology, there are several publicly tradeable companies utilizing the power of CRISPR gene editing, base editing, and prime editing in the Kelly CRISPR & Gene Editing Technology ETF (Nasdaq: XDNA). Two of the XDNA companies are about to make history with potentially the first ever commercially available CRISPR technology.
***First FDA Approved Treatment - Major Milestone for the CRISPR Revolution: XDNA companies, CRISPR Therapeutics, 12.18%, and Vertex Pharmaceuticals, 1.56%, are anticipated to get the first ever U.S.-marketed treatment based on CRISPR this year for their Exa-cel therapeutic (data as of April 18, 2023).
CRSP- Based on 17 analysts giving stock ratings to Crispr Therapeutics AG in the past 3 months
CRSP Stock 12 Months Forecast
Based on 17 Wall Street analysts offering 12 month price targets for Crispr Therapeutics AG in the last 3 months. The average price target is $75.65 with a high forecast of $143.00 and a low forecast of $42.00. The average price target represents a 17.05% change from the last price of $64.63.
Don't know how you live with yourself. Going from board to board pump and dumping and lying to people.
You should delete this post quickly before people wizen up to you.
DBMM; Interesting Story:
***By:LOVE*PINK- Sunday, May 21, 2023 - Post# 300172
$DBMM is OTC once in a LIFETIME opportunity.
We will probably NEVER find another story like $DBMM.
Fighting against all odds and winning against GOVERNMENT and 100% revocation guarantee is not common.
These are once in a lifetime events.
$DBMM WINNING it ALL.
Not 1 time but EVERY TIME.
Backed by Harvard Grad CEO Linda, COO Reggie James and one of the nation's best SEC attorney Maranda Fritz.
And yes - not to forget - very strong shareholder base.
$DBMM becoming the BEST in OTC. Target NASDAQ.
From GREY --> PINK --> OTCQB --> NASDAQ.
With GROWTH and ACQUISITIONS..
ALL COMING TOGETHER - 1 step at a time.
We are almost there to WIN IT ALL.
Blessed to be part of $DBMM story as a shareholders.
CRSP- CRSP - CRISPR Therapeutics Revenues and Earnings Beat Expectations
***Earnings per share (EPS) also surpassed analyst estimates by 59%. Looking ahead, revenue is forecast to grow 58% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.10 hours ago
CRISPR Therapeutics First Quarter 2023 Earnings
https://ca.finance.yahoo.com › news › crispr-therapeutics...
***How to Buy Penny Stocks
The OTC Stocks Being Less Regulated they are subject to Scare Tactics and Manipulation!.......
***Once you've learned to dodge the scammers, there are five steps to follow when purchasing a penny stock.
It's important to evaluate whether the stock has upside potential. You're investing because you'd like to get a return, right? So you need to ask yourself whether the penny stock you're considering truly has upside potential, or if it seems more to be a flavor-of-the-day stock, such as a company that's trying to ride the coattails of the latest investment fad.
***The Bottom Line
Penny stocks are extremely volatile and speculative by nature. As most trade on OTC exchanges or via pink sheets, where listing standards are lax, penny stocks are susceptible to manipulation and fraud. Still, the potential to make large returns is a strong allure, driving risk-taking investors into taking positions in these securities. Though many penny stocks go bust, if an investor exercises careful fundamental analysis and picks sound management teams, they could find the coveted diamond in the rough.
CRSP - Interesting Video from Dylan Jovine
DYLAN JOVINE CLAIMS THE NEXT BIG BIOTECH TAKEOVER IN 2020 WILL BE A” CUT AND PASTE” COMPANY
"This report tells you everything you need to know about this incredible company --- and why the world’s leading scientist believe its CRISPR technology is the best, giving you the chance to for a 46,751% return"
<< It could help you achieve the kind of carefree retirement most people only dream of. But what if this turns out to be your biggest opportunity? How long will you stay in the dark>>? Continue reading...
GRST -FROM OTC MARKET -
DATE TIMESTAMP PRICE $ CHANGE VOLUME
04/03/2023 15:55:00 0.0004---0.00-------50,000
04/03/2023 15:49:07 0.0004---0.00-------15,000
04/03/2023 12:56:57 0.0005 ---0.00------1,000,000
04/03/2023 12:45:01 0.0004---0.00--------60,000
04/03/2023 12:44:52 0.00045---0.00------10,000
04/03/2023 09:36:26 0.0004---0.00--------55,000
04/03/2023 09:36:21 0.0004---0.00--------10,000
04/03/2023 09:36:12 0.00045---0.00-------10,000
03/31/2023 15:59:32 0.0005---0.000------100,000
03/31/2023 15:57:06 0.00045---0.00-------500,000
CRISPR - Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting
March 14 2023 - 06:02PM
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation of preclinical data at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place April 14 – 19, 2023, in Orlando, FL.
Title: CTX112 and CTX131: Next-generation CRISPR/Cas9-engineered allogeneic (allo) CAR T cells incorporating novel edits that increase potency and efficacy in the treatment of lymphoid and solid tumors
Session Type: Drug Development Special Track Session
Session Title: New Drugs on the Horizon: Part 1
Location: Tangerine Ballroom 2, Convention Center
Date and Time: April 16, 2023, 1:25 – 1:40 p.m. ET
The data are embargoed until the beginning of the Drug Development Special Track Session: New Drugs on the Horizon: Part 1 at 1:00 p.m. ET on April 16, 2023. A copy of the presentation will be available at www.crisprtx.com once the presentation concludes.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.
Thank you JC and yes I was little bambi (the old
Alias). I asked Ihub to change it lol
I will take a look of what you sent
Thank you again
*** CRSP - Could CRISPR Therapeutics Help You Become a Millionaire?
***From MOTLEY FOOL....
***CRISPR Technologies[: 191,416% implied sales growth by 2025
Did I mention that clinical-stage biotech stocks are a great source of jaw-dropping growth over the next decade? CRISPR Therapeutics (CRSP -5.61%), a company leaning on gene-editing technology to precisely alter genomic DNA and tackle hard-to-treat diseases, is expected to see sales climb from $719,000 in 2020 to a consensus of $1.377 billion by 2025. That's an improvement of more than 191,000% in five years.
Arguably the biggest positive for CRISPR is that it's working with Vertex Pharmaceuticals (VRTX 0.12%) in the development of CTX001 for the treatment of transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD). Vertex has a storied history of developing novel therapies for hard-to-treat illnesses, such as cystic fibrosis.
It also doesn't hurt that Vertex's deep pockets are helping to lift CRISPR's bank account. Following a $900 million collaboration payment in the second quarter, CRISPR was sitting on nearly $2.6 billion in cash, cash equivalents, and marketable securities. That's plenty of capital to fund its ongoing clinical studies.
Initial trial data for CTX001 has also been encouraging. At the European Hematology Association's annual meeting in June, the company announced that all 15 patients with TDT were transfusion-free after follow-ups of at least three months. TDT patients can require weekly transfusions, depending on the severity of their illnesses. Management believes regulatory filings, assuming all goes well in clinical studies, could come by or before mid-2023.
While CRISPR Technologies is far from the only company looking to tackle TDT and SCD, it's among the best funded and has Vertex in its corner. That gives it a better-than-average chance of success, at least in my book.
***4 Stocks Expected to Increase Sales 25,750% to 2,970,000% in 5 Years
By Sean Williams – Sep 30, 2021 at 5:51AM
Revenue growth alone doesn't always tell the full story about a company's prospects.
Motley Fool Issues Rare “All In” Buy Alert
GRST - DOWNLOAD OF ETHEMA HEALTH CARE PODCAST VIDEO
Uptick Newswire’s Stock Day Podcast Features Shawn Leon, Ethema Health Corporation CEO, To Discuss the New Facility in Florida and Their Unique Approach to Payer Groups
December 11, 2018 08:30 ET | Source: Ethema Health Corporation
PHOENIX, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Uptick Newswire Stock Day Podcast features Ethema Health Corporation (OTCQB: GRST) ("Ethema" "GRST" or the "Company"), a provider of healthcare services including addiction and mental health. Shawn Leon, President and CEO, talked with Stock Day’s Everett Jolly about a new chapter for the company.
“We’ve been in the addiction treatment business for about 8 years now, we started in Canada and operated a Best in Class treatment facility in Canada. We wanted to expand into the US and in 2017 we sold the Canadian business and started the expansion into the US with a facility in Florida,” Leon said at the start of the interview.
Jolly then asked about that facility in Florida. He mentioned it’s an 80 thousand sq. foot facility on over 8 acres with about 175 beds. Jolly asked Leon to bring listeners up to speed. Leon said they have been working on getting the facility since late 2017 and took possession in May of 2018.
“We are now up and fully operating as of mid-October 2018. We have all levels of care, detox, intensive in-patient care, residential care, partial hospitalization, intensive outpatient care and outpatient care,” explained Leon. “It’s been a tough process to get the facility open and to get the staff in place and get everything going we the way we want it, but we are there now and see a lot of great treatment days ahead of us.”
Jolly then asked how the company finds their clientele. Leon explained they do something a bit different than most treatment facilities. He said most facilities advertise to the clients, but they have a more direct approach.
“We go direct to the payer groups, for example the Union group that has a self-directed healthcare plan, we would deal directly with the Union or employer assistance programs that are part of an employer management of their healthcare.” He added, “We are primarily trying to get the groups to recognize us as leaders and Best in Class treatment providers with great value.”
He went on to say they provide a high-quality and effective care at a good price. Jolly said he thinks the company is in the right space because of the opioid epidemic. Leon replied that because of the epidemic, there is a focus on the addiction treatment business in general. He said it’s encouraging that people are recognizing those with addiction need help.
“A lot of the opioid users, are not getting the treatment they need because most of the payers are focused on cost. They cut the treatment stay as short as possible,” he explained. “It takes a much longer period of time to withdraw from and get the opioid addiction out of the body.
He said that why they’ve gone direct to employer groups to explain that it’s better to get it done right the first time instead of trying over and over again. Jolly then asked if they are looking at any of the cannabinoid products, like CBD.
“We’ve been approached my many of the people in the cannabis business,” Leon said. “We ourselves being a treatment center in Florida where these things aren’t legal can’t conduct that kind of research in the US. We think there may be something there but that research has to be done and it will take some time to tell how effective it can be.”
Jolly then noted in 2017 the company did $920,000 in revenue and asked Leon what he saw happening with Ethema in 2019. He said the facility in Florida will generate revenue for the 4th quarter above all of last year.
“The facility at full capacity would generate in the $35 to $40 million revenue range. We don’t know that we’ll fill the facility for the full year 2019, but we expect to get there fairly quickly. We can expect significant improvements to revenue,” said Leon.
To hear the full interview with Ethema’s CEO, listen to the Stock Day Podcast, here. https://upticknewswire.com/featured-interview-ceo-shawn-leon-of-ethema-health-corporation-otcqb-grst-2/
About Ethema Health Corporation
Ethema Health Corporation (OTCQB: GRST) operates in the behavioral healthcare space specifically in the treatment of substance use disorders. Ethema developed a unique style of treatment over the last six years and has had much success with in-patient treatment for adults. Ethema will continue to develop world class programs and techniques with its expansion in the United States. The Company currently has under twenty employees and operates in Delray Beach, Florida. For more information you can visit our website at www.ethemahealth.com and seastoneofdelray.com
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Mr. Shawn Leon
President and CEO
Ethema Health Corporation
About Uptick Newswire and the “Stock Day” Podcast
Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its “Stock Day” Podcast, which is the number one radio show of its kind in America. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.